1.5.8 Ensure that there is a regular multidisciplinary team meeting to discuss the risks and benefits of continuing drug treatment or revascularisation strategy (CABG or PCI) for people with stable angina. The team should include cardiac surgeons and interventional cardiologists. Treatment strategy should be discussed for the following people, including but not limited to: people with left main stem or anatomically complex three-vessel disease people in whom there is doubt about the best method of revascularisation because of the complexity of the coronary anatomy, the extent of stenting required or other relevant clinical factors and comorbidities. 1.5.9 Ensure people with stable angina receive balanced information and have the opportunity to discuss the benefits, limitations and risks of continuing drug treatment, CABG and PCI to help them make an informed decision about their treatment. When either revascularisation procedure is appropriate, explain to the person: The main purpose of revascularisation is to improve the symptoms of stable angina. CABG and PCI are effective in relieving symptoms. Repeat revascularisation may be necessary after either CABG or PCI and the rate is lower after CABG. Stroke is uncommon after either CABG or PCI, and the incidence is similar between the two procedures. There is a potential survival advantage with CABG for some people with multivessel disease. 1.5.10 Inform the person about the practical aspects of CABG and PCI. Include information about: vein and/or artery harvesting likely length of hospital stay recovery time drug treatment after the procedure. 